We’re a different kind of biotech company.
And we’re here to make a difference


(Voice over and music under a montage of real people.)

Patients with inflammatory bowel disease live in a world of pain, with increased anxiety and reduced quality of life.

Despite access to advanced therapies, many still experience complications leading to hospitalizations and surgery.

Each patient’s disease is different.

Many struggle to find a treatment that works and have given up hope, but hope for more precision is precisely what they need.

(Transition to graphic of a star constellation)

So, we’re creating transformational change.

It’s time to start patients on the right treatment the first time around.

Introducing Prometheus 360™ a one-of-a-kind discovery engine designed to enable new levels of precision.

(Images of data and DNA visualizations)

Our expert scientists are harnessing the power of cutting-edge data science and machine learning, to continually identify new drug targets and unique disease biomarkers.

Leveraging the world’s most comprehensive collection of IBD patient data featuring over 200,000 samples linked to 20 years of longitudinal clinical data from more than 20,000 patients.

(Montage of workers in lab)

We’re reimagining how these clinical data profiled across genetics, serologics, and transcriptomics can uncover novel immune-mediated networks that drive disease.

And it’s led us to new targeted therapeutic candidates.

(PRA023 title graphic)

Like PRAO23, an anti-TL1A monoclonal antibody designed to address both intestinal inflammation and fibrosis in patients with Crohn’s disease and ulcerative colitis, along with a companion diagnostic product candidate designed to identify patients more likely to respond to our targeted therapies…

(Back of woman walking outside in sunlight)

offering the potential to reduce drug development times and offering patients the possibility of monumental gains in efficacy.

A one-of-a-kind precision approach that will help us…

(Graphic showing particles that assemble into points on a body.)

transform treatment for patients is at the center of what we do…

(Graphic of body transitions to reveal inside organs.)

at Prometheus Biosciences. And it’s here to help patients find the right treatment for their unique biomarker profile.

IBD is just the start.

(Title overlay lists: multiple active therapeutic programs, many others in discovery, targeting a new IND every 12-18 months)

Our pipeline is expanding rapidly with the promise of going beyond GI diseases.

(Montage of happy real people looking into camera)

To help more patients with autoimmune diseases, giving them new opportunities to start with targeted treatment and new reasons to hope.

That’s the power of precision.

(Prometheus Biosciences logo)

That’s the power of Prometheus Biosciences.

At Prometheus Biosciences, we aim to transform the paradigm of patient care with a proprietary precision-based approach to IBD and immune-mediated diseases. By harnessing the power of machine learning and leveraging the world’s most comprehensive collection of IBD patient data.

We’re not just changing the game. We’re changing lives. With the promise of targeted treatments.

The story of Prometheus Biosciences

It all started more than 20 years ago at Cedars-Sinai Medical Center where one of our founders, IBD luminary Dr. Stephan Targan, began building the IBD biobank. He recognized the potential of pairing IBD patient bio-samples with longitudinal clinical data—and this research led to the discovery of TL1A, the target of our lead program.

Dr. Stephan Targan.

Dr. Stephan Targan

Cedars Sinai logo.
Dr. Dermot McGovern.

Dr. Dermot McGovern

Dr. Janine Bilsborough.

Dr. Janine Bilsborough

The IBD biobank continued to evolve under the guidance of Dr. Dermot McGovern, who provided key genetics and computational expertise. Dr. Janine Bilsborough brought biotech and industry expertise, and spearheaded enhanced approaches to translating the learnings gleaned from the biobank into novel therapeutic strategies.

In 2016, with significant investment and the support of Cedars-Sinai’s Technology Transfer Office led by Jim Laur, the founders partnered with serial entrepreneur Scott Glenn to form a new company. The goal: to capitalize on their vision, the first precision medicine approach to IBD. Initially named Precision IBD, the company later became Prometheus Biosciences.

Cedars-Sinai and their exceptional IBD team remain close partners and collaborators, as we continue to develop new medicines for IBD and beyond.

Jim Laur.

Jim Laur

Scott Glenn.

Scott Glenn

Dr. Tadataka "Tachi" Yamada.

In 2018, Prometheus Biosciences was fortunate to attract industry titan Dr. Tadataka “Tachi” Yamada to serve as Chairman of our Board of Directors, a position he held until his untimely passing in August 2021. Dr. Yamada brought immense drug development insights from his prior roles as Chief Medical and Scientific Officer at Takeda Pharmaceuticals, President of the Bill & Melinda Gates Foundation, and Board Director for numerous biotechnology organizations.

Our team will always remember the immeasurable contributions that Dr. Yamada has made to our organization–and to our lives. We carry on the important work of bringing precision medicine to immune-mediated diseases as a tribute to his memory.

See our mission